• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A pertussis toxoid is produced by removing endotoxin from a culture supernatant of a Bordetella pertussis phase I strain or a concentrate thereof and flocculating pertussis exotoxin in the resultant fluid by permitting formaldehyde to act upon the fluid in the substantial absence of basic amino acid. The thus-obtained pertussis toxoid is low in toxicity and has a high immunizing potency.
    公开号:SU1297712A3
    申请号:SU813235495
    申请日:1981-01-23
    公开日:1987-03-15
    发明作者:Сиукуда Юкио；Ватанабе Хидео；Мацуяма Сигео
    申请人:Такеда Кемикал Индастриз,Лтд. (Фирма)；
    IPC主号:
    专利说明:

    This invention relates to biotechtology and is concerned with the preparation of biologically active substances.
    The aim of the invention is to reduce the toxicity of the target product by modifying the method of isolation and detoxification.
    The method is illustrated by a simple example.
    Example 1, and Tohamafaz111 1 Bordetella pertussis, is inoculated on Burde-Gangu medium prepared from potatoes, peptone, sodium chloride, agar and bovine blood, and incubated at 35 ° C for two days. Then translucent round colonies are selected, the activity of K-agglutinating serum is determined, and the culture is selected as a seed. The production medium is obtained by autoclaving a Cohe-Wheeler liquid medium containing: soluble starch 225 g, sodium chloride 375 g, disubstituted potassium phosphate 75 g, magnesium chloride hexahydrate 750 ml (8% w / v,% liquid), calcium chloride 75 ml ( 2 w / v,% liquid), copper sulfate pentahydrate 112.5 ml (0.1 w / v% liquid), sodium glutamate 30 g, nicotinamide 4.5 g, casamic acid 1800 g, cystine hydrochloride 4.5 g, Tris buffer 12.5 l. The components of the medium are diluted with distilled water to 150 liters, adjusted to pH 7.0-7.2 and sterilized, then glutathione (recovered 50 ml (| w / v% liquid) and Fe5047H 50 ml (l Fluid at 121 ° C for 60 minutes, followed by rapid cooling to approximately 40 ° C. The medium is stored at 37 ° C,
    The inoculum culture is introduced into the nutrient medium to a final concentration of 200-300 ppm, cells / ml, mixed thoroughly, seeded at 0.2 l in the Rowks’s bottle and placed in a thermostat at 37 ° C. The maximum number of cells is obtained on the 5th day. liquids from bottles are combined, centrifuged, and 20.2 w / v, ammonium sulfate is added to the supernatant. After thorough mixing, the mixture is kept at 4 ° C. After 7 days, the supernatant is drained and the precipitate is collected and centrifuged at 8000 rpm for 10 minutes.
    five
    0
    five
    0
    five
    0
    3
    0
    five
    the sedimentary liquid is discarded, 1/10 volume of the mixture W of sodium chloride solution and (), 05 M phosphate buffer (pH 8.0) is added to the precipitate and the mixture is thoroughly mixed. The mixture is again maintained at 40 ° C for 7 days, after which it is again centrifuged and the supernatant is collected (extract 1),
    Extract 1 contains fibrin, a leukocytosis promoter factor (PSL), gmintaminimmunizing factor (HIF) and endotoxin, there are no microbial cells. Extract 1 is re-concentrated, an equal volume of a saturated ammonium sulphate solution (pH is adjusted with ammonia) is added to it and the mixture is kept at 4 ° C for 7 days. The ammonium sulfate fraction is centrifuged at 10,000 rpm for 20 minutes, the precipitate is separated and 1/300 of the volume of the liquid mixture Ш of sodium chloride solution and 0.05 M phosphate buffer (pH 8, o) is added. After thoroughly mixing, the mixture is placed in A dialysis tube with a semipermeable membrane to remove ammonium sulfate and dialysis are carried out against a 1M solution of sodium chloride (pH 8.0). The dialyzed concentrate is then centrifuged at a sucrose density gradient.
    The pre-sterilized 1700 ml centrifuge rotor and the sealed unit are rotated at a low speed; 1300 ml 5-30 w / v% sugar-free solutions are fed using a gradient pump. Then 100 ml of a dialyzed concentrate are fed and the coating medium is introduced (0.5 M sodium chloride solution, pH 8.0). The rotor is rotated at RMQ 89400 and for 18.5 hours.
    After centrifugation, 34 w / v% sugar cane solution is fed at low speed and the liquid from the rotor is collected in fractions of 50-100 ml. The collection of fractions is started from the low density side of sucrose, and fractions with high hemagglutinating activity (at least 20 units / ml, preferably at least 500 units / ml) and depleted in endotoxin are obtained. The presence of endotoxin is determined in a test in rabbits. Each sample of the fraction was kept at 100 ° C for 3 minutes and diluted to
    312
    20 hematsinigrupsch units / ml of saline. The skipped sample is administered intravenously to rabbits at a dose of 1 ml / kg live weight. Fractions that do not cause heat in rabbits for 3 hours are collected and pooled as the desired product (exotoxin).
    The collected fractions containing the exotoxin were diluted with M / 250 phosphate buffer pH 7.0 to a protein content of 50 mg / ml. Gelatin, tween-80 and thimerosol are added to a final concentration of 0.02% w / v, 0.05% v / v and 0.01% w / v, respectively, to the mixture without which - Formalin is added to the basic amino acid to a concentration of 0.2% v / v in a thermostat at 39 ° C and, after thorough mixing, the mixture is further incubated in the same thermostat. After 2 days, formalin is added to a concentration of 0.3 v / v% and, after thorough mixing, the mixture is further incubated at the same temperature.
    After 2 days, the addition of formalin was repeated to a concentration of 0.4 v / v% and, after stirring, the incubation was continued for 5 days.
    You can handle a mixture of 0.1 v / v% formalin by incubating at 42 ° C for 14 days or 0.6 v / v formalin by incubating for 14 days.
    The resulting toxoid flocculent suspension is dialyzed with 0.01 v / v / v of formalin-saline, identical to the coating medium. Dialysis is carried out in a membrane dialysis tube at a 12.5-fold ratio of the volumes of the internal and dialysis solution for 2 days, while the dialysis solution is constantly stirred. After two days, this solution was replaced with a fresh solution and the dialysis was repeated. The dialyzed toxoid toxoid flocculent suspension is subjected to various tests applied to the cocklet vaccine raw material.
    sha.
    Next, the suspension of toxoid flakes is subjected to ultrasonic treatment (frequency 20-50 kHz, 5 min) and filtered through a coarse filter.
    g
    Q 5 0 5
    0
    five
    0
    ,
    0
    five
    124
    400 mesh, resulting in a liquid pertussis toxoid.
    The experience of treating the liquid containing exotoxin with formalin with the addition of 0.05 M L-lysine was monitored and then the treatment was carried out as described above.
    Experimental and control liquids separately treated by the method of Levin. Each liquid was diluted with M / 250 phosphate buffer pH 7.0 to a protein content of 20 µg / ml or less, and aluminum chloride was added to a concentration of 0.18 w / v. The mixture is thoroughly mixed, the pH is adjusted to 7.0 with hydrochloric acid or sodium hydroxide and the precipitated precipitate is separated.
    vaccine, 1
    The experiments showed the following: BLP should not exceed the equivalent of 0.5 LUE (leukocytosis of the promoter unit) / ml; The HIF should not exceed the equivalent of 0.8 GSE (histamine-sensitizing units) / ml; Efficacy of mummy is acceptable when it is 8 MU (infection three weeks after immunization) per ml.
    The average efficacy of 14 consecutive batches is 13.5 IU / ml. In the control (with the addition of L-lysine), a series of 23 batches shows complete acceptability of the vaccine in only 23%,
    Example 2. Liquid pertussis toxoid obtained in Example 1, diphtheria liquid toxoid and tetanus toxoid are precipitated in accordance with Example 1 and purified polyvaccine against pertussis — diphtheria – tetanum is obtained.
    The composition of the vaccine: pertussis toxoid - protein content of about 15 mg / ml, diphtheria toxoid - approximately 30s 1 / ml; tetanus toxoid - approximately 5 °, / ml; aluminum — about 0.2 mg / ml; thimerosol 0.01 wt./about.%.
    Polyvaccine has the following basic properties: the concentration of hydrogen ions is 7.0; Pyrolysis for rabbits (50-fold dilution and intravenous administration at a rate of 1 ml / kg live weight) is negative; weight loss does not exceed the permissible norm; leukocytosis promotion activity in mice no more than the equivalent of 0.5 LU / ml; histamine sensitization activity no more than equivalent 0.8 efficiency
    512
    pertussis toxoid is equivalent to 8 IU / ml, diphtheria toxoid is 45 IU / mp, and tetanus toxoid is 30 IU / ml.
    Vaccination is carried out as follows.
    Children 3-48 months of age, subcutaneously injected 0.5 ml of each vaccine three times with an interval of 2-8 weeks. After 12-18 months, after the last injection, another 0.5 ml of the vaccine was injected subcutaneously.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    The method of obtaining toxoid Vogo- detella pertussis by cultivating bacteria in the first phase in the diet. Editor L. Veselovska Order 799/64
    Compiled by G. Smirnova Tehred M. Khodanych
    Corrector L
    Circulation 596 Subscription
    VNISH1I USSR State Committee
    for inventions and discoveries 113035, Moscow, Zh-35, Raushsk nab., 4/5
    Production and printing company, Uzhgorod, Projecto st., 4
    26
    a medium with subsequent separation of biomass, release of the toxin from the culture liquid and its detoxification, characterized in that, in order to reduce the toxicity of the target product, a mixture of toxins is precipitated from the culture liquid after separation of the mycelium, the precipitate is diluted with a buffer solution with sodium chloride, the resulting concentrate, if necessary, is additionally concentrated by treatment with ammonium sulfate and dialysis, exotoxin is isolated, treated with a formaldehyde solution in a ratio of 1: 0.1-0.6 v / v / v and the obtained target product is subjected to ultrasonic treatment at a frequency of 10-50 kHz.
    Proofreader L. Pat Ai
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1297712A3|1987-03-15|Method for producing bordetella pertussis anatoxin
    Harris-Smith et al.1958|Production in vitro of the toxin of Bacillus anthracis previously recognized in vivo
    Tosa et al.1971|L-asparaginase from Proteus vulgaris
    US4784589A|1988-11-15|Purification of pertussis antigens
    US4220584A|1980-09-02|E. coli enterotoxin vaccine for veterinary and human use
    Heckly et al.1958|TOXINS OF PSEUDOMONAS PSEUDOMALLEI II: Characterization
    KR940004541B1|1994-05-25|Treponema hyodysenteriae bacterin and process for preparing thereof
    KR900007644B1|1990-10-17|Method for culturing bordetella pertussis,a perussis toxoid and a pertussis vaccine
    RU2089216C1|1997-09-10|Method of removing endotoxin from the strain bordetella pertussis cultural fluid phase i
    SK111193A3|1994-03-09|Bacterial macromolecule extract, method for preparing same and pharmaceutical composition containing said extract
    Gledhill et al.1957|The toxicity of some bacterial filtrates for mice pre-infected with Eperythrozöon coccoides
    US4016260A|1977-04-05|Novel polypeptide produced by pseudomonas
    Wadsworth et al.1928|The attenuation and toxin production of the diphtheria bacillus. 1. Attenuation of the diphtheria bacillus. 2. Synthetic mediums. 3. Factors affecting growth and toxin production
    US3438865A|1969-04-15|Preparation of bacterial lipopolysaccharides
    Pasternak et al.1951|The inhibition of yeast carboxylase by homologous antiserum
    Mueller1935|Studies on Cultural Requirements of Bacteria: VI. The Diphtheria Bacillus
    US2602041A|1952-07-01|Method for the manufacture of polymyxin
    EP0084334A1|1983-07-27|Polysaccharide substance, process for the production of same, pharmaceutical compositions containing the same and their use as medicaments
    CN114149973A|2022-03-08|Composition for inducing H22 cells to express calreticulin and method for producing calreticulin by using composition
    KR100787830B1|2008-01-02|The preparing method of inactivated vaccine of Swine Erysipelas prepared with inactivated antigen and specific purified protein antigen of Swine Erysipelas
    RU2407792C1|2010-12-27|METHOD FOR PRODUCING IgAl-PROTEASE FROM SEROGROUP A NEISSERIA MENINGITIDIS AND RELATED IMMUNOGENIC PREPARATION
    SU1750690A1|1992-07-30|Method for preparation of escherichia coli conjugated enterotoxin
    Arima et al.1972|Isolation of the Citrate Transport-enhancing Factors from Aerobacter cloacae
    SU526295A3|1976-08-25|Method for producing lysine
    RU2089215C1|1997-09-10|Method of preparing meningococcus lipopolysaccharide of serogroup b
    同族专利:
    公开号 | 公开日
    NO159667B|1988-10-17|
    NO810014L|1982-03-15|
    DK155915B|1989-06-05|
    ES8202058A1|1982-02-01|
    EP0047802B1|1984-10-10|
    JPS5750925A|1982-03-25|
    EP0047802A2|1982-03-24|
    DE3069433D1|1984-11-15|
    DK155915C|1989-10-23|
    US4455297A|1984-06-19|
    KR830004851A|1983-07-20|
    DK9281A|1982-03-13|
    KR840001512B1|1984-09-29|
    GB2083358A|1982-03-24|
    HU185404B|1985-02-28|
    CA1152001A|1983-08-16|
    JPS64928B2|1989-01-10|
    ES499112A0|1982-02-01|
    NO159667C|1989-02-01|
    EP0047802A3|1982-12-29|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB512196A|1937-08-19|1939-08-30|Lederle Lab Inc|Method of preparing pertussis toxin and toxoid|
    US2359388A|1941-02-13|1944-10-03|Lederle Lab Inc|Method of preparing pertussis toxin and toxoid|
    US3135662A|1961-01-05|1964-06-02|Burroughs Wellcome Co|Diphtheria toxoid preparation and its production|
    NL6600706A|1965-02-05|1966-08-08|
    US4070454A|1973-05-04|1978-01-24|Agence Nationale De Valorisation De La Recherche |Vaccines, the process for preparing the same and the applications thereof|
    DE2448530C3|1974-10-11|1980-03-27|Behringwerke Ag, 3550 Marburg|Process for the preparation of derivatives of diphtheria toxin and compositions containing them|
    DE2457047C3|1974-12-03|1979-10-31|Behringwerke Ag, 3550 Marburg|Process for the preparation of a derivative of the light chain of tetanus toxin, its use for tetanus prophylaxis|
    FR2393065B1|1977-05-31|1981-01-09|Merieux Inst|JPS59206316A|1983-05-11|1984-11-22|Kaken Pharmaceut Co Ltd|Active substance derivative for enhancing secretion of insulin and production thereof|
    US4551429A|1983-09-15|1985-11-05|American Home Products Corporation|Stimulation of antigen production by Bordetella pertussis|
    US4563303A|1984-04-14|1986-01-07|Judicial Foundation The Chemosero-Therapeutic Research Institute|Method for purification of filamentous hemagglutinin|
    GB8412207D0|1984-05-12|1984-06-20|Wellcome Found|Antigenic preparations|
    JPS60155127A|1984-12-10|1985-08-15|Teijin Ltd|Preparation of biologically active substance|
    GB8512972D0|1985-05-22|1985-06-26|Univ Glasgow|Vaccine production|
    GB8601279D0|1986-01-20|1986-02-26|Public Health Lab Service|Purification of pertussis antigens|
    FR2597344B1|1986-04-16|1989-06-23|Merieux Inst|IMPROVEMENT IN THE PROCESS OF PURIFYING PROTEIN ANTIGENS FROM BACTERIA BELONGING TO THE GENUS BORDETELLA, WITH A VIEW TO OBTAINING A CELLULAR VACCINE.|
    US4705686A|1986-05-09|1987-11-10|American Cyanamid|Process for the preparation of acellular Bordetalla pertussis vaccine|
    US5032398A|1986-08-01|1991-07-16|Kaslow Harvey R|Selective modification of the catalytic subunit of pertussis toxin|
    US5165927A|1986-08-01|1992-11-24|University Of Southern California|Composition with modified pertussis toxin|
    US5139776A|1987-04-24|1992-08-18|The Research Foundation For Microbial Diseases Of Osaka University|Method for culturing Bordetella pertussis, a pertussis toxoid and a pertussis vaccine|
    CA1337859C|1987-04-24|1996-01-02|Masashi Chazono|Method for culturing bordetella pertussis, a pertussis toxoid and a pertussis vaccine|
    US5101019A|1987-05-22|1992-03-31|Takeda Chemical Industries, Ltd.|Method for removing pertussis endotoxin, a pertussis toxoid and its production|
    JPS6485926A|1987-06-24|1989-03-30|Teijin Ltd|Mutant of bordetella pertussis|
    GB8807860D0|1988-04-05|1988-05-05|Connaught Lab|Pertussis vaccine|
    JP2706792B2|1988-11-29|1998-01-28|財団法人化学及血清療法研究所|Toxoidation of pertussis toxin|
    DK0396964T3|1989-04-28|1995-10-30|Sclavo Spa|Pertussis toxin mutants, Bordetella strains capable of producing such mutants, and their use in the development of antipertussis vaccines|
    GB8910570D0|1989-05-08|1989-06-21|Wellcome Found|Acellular vaccine|
    US5578308A|1990-02-12|1996-11-26|Capiau; Carine|Glutaraldehyde and formalin detoxified bordetella toxin vaccine|
    WO1991012020A1|1990-02-12|1991-08-22|Smithkline Beecham Biologicals |Novel vaccine and method therefor|
    JPH0432188U|1990-07-10|1992-03-16|
    AU667858B2|1991-11-15|1996-04-18|Smithkline Beecham Corporation|Gram-negative bacterial vaccines|
    JP2634545B2|1992-10-27|1997-07-30|日本全薬工業株式会社|Method for producing a bacterial toxin vaccine belonging to the RTX toxin family|
    DE69511392T2|1994-04-28|2000-03-23|Takeda Chemical Industries Ltd|METHOD FOR SEPARATING PROTECTIVE CONNECTIONS FROM BORDETELLA PERTUSSIS|
    BRPI0402630B8|2004-07-05|2021-05-25|Fund Butantan|process of obtaining a less reactogenic cellular pertussis vaccine|
    RU2504399C1|2012-12-06|2014-01-20|Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским и иммунопрофилактическим препаратам "Микроген" Министерства здравоохранения Российской Федерации |Method for preparing cell-free vaccine for pertussis immunisation|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    JP55127825A|JPS64928B2|1980-09-12|1980-09-12|
    [返回顶部]